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Abstract A nanorobot is defined as any smart structure
which is capable of actuation, sensing, manipulation, intelli-
gence, and swarm behavior at the nanoscale. In this study, we
designed an intelligent system using fuzzy logic for diagno-
sis and treatment of tumors inside the human body using
bionanorobots. We utilize fuzzy logic and a combination of
thermal, magnetic, optical, and chemical nanosensors to
interpret the uncertainty associated with the sensory infor-
mation. Two different fuzzy logic structures, for diagnosis
(Mamdani structure) and for cure (Takagi–Sugeno structure),
were developed to efficiently identify the tumors and treat
them through delivery of effective dosages of a drug. Vali-
dation of the designed system with simulated conditions
proved that the drug delivery of bionanorobots was robust
to reasonable noise that may occur in the bionanorobot
sensors during navigation, diagnosis, and curing of the can-
cer cells. Bionanorobots represent a great hope for successful
cancer therapy in the near future.
Keywords Bionanorobot . Control system . Drug delivery .
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1 Introduction
Nanomedicine is the technology that uses nanoscale or nano-
structured materials such as bionanorobots in medicine that
according to their structure have unique medical effects
(Wagner et al. 2006). A nanorobot is a smart structure that
is capable of intelligent behavior such as actuation, sensing,
signaling, information processing, manipulation, and swarm
behavior at the nanoscale. Bionanorobots are nanorobots
designed and inspired by harnessing properties of biological
materials such as peptides and DNAs (Freitas 2006).
Bionanorobots present multiple clinical uses including
targeted drug delivery, nanosized hybrid therapeutics (low
dosage), and early diagnosis at the cellular level (Zhou and
Wang 2011). Bionanorobots present a great hope for the
treatment of many diseases and conditions including cancer,
AIDS, and diabetes. This emerging technology for drug
delivery is based on the synergy between several disciplines
including biology, chemistry, physics, engineering, and com-
puter science. The first uses of nanorobots in healthcare are
expected to be developed within the near future and could
have a wide range of biomedical applications (Cavalcanti
et al. 2008a; Zhou and Wang 2011).
The potential use of bionanorobots for drug delivery in
cancer treatment has multiple advantages over current che-
motherapy and radiation techniques. When chemotherapy
drugs are ingested or injected, the drug travels throughout
the body targeting fast growing cells such as cancer cells and
other healthy fast growing cells. This can cause degenerative
health effects (Cavalcanti et al. 2008a) such as damage to the
digestive tract and heart as well as unfavorable side effects
such as hair loss. The damaging side effects limit the dose of
the drug administered effectively reducing the amount of the
drug that reaches the tumor. In a targeted drug delivery
system, the drugs are given directly to the tumor cells that
are identified by the bionanorobots. This would reduce the
negative side effects and improve the patient's quality of life
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during and after the treatment (Cavalcanti et al. 2008b;
Karan and Majumder 2011). In addition, the dose of the drug
that reaches a tumor cell can be controlled and even in-
creased because of the reduced risk of harmful side effects.
Due to the differences in material and the range of scale,
the design and control techniques of bionanorobotics are
distinctly different than that of macro robotics. It is impera-
tive to note that the actual environment surrounding the
bionanorobot inside the human body is a world of viscosity,
where friction, adhesion, and viscous forces play a signifi-
cant role, while the gravitational force is negligible. The
turbulence is not present in the fluid stream due to low
Reynolds number. However, fluid shear stress is a major
factor that could hamper the bionanorobot due to the robot's
traveling speed and the nanoscale size. The challenges asso-
ciated with the deployment of bionanorobots inside the hu-
man body for drug delivery and other medical applications
include loop control (Cavalcanti and Freitas 2005) and guid-
ance at the nanoscale and wireless communication for the
data transfer (Cavalcanti et al. 2006), accurate modeling of
tracking behavior, and power generation at the nanoscale.
Some suggested tools for the control of bionanorobots in
literature include fuzzy logic, artificial intelligence, and neu-
ral networks (Cavalcanti et al. 2004). As such, there are no
established set of guidelines currently available detailing the
methods of designing and navigating a bionanorobot effi-
ciently inside the human body.
In the aorta, which is the largest artery coming from the
heart, the averaged velocity is 33 cm/s. This value depends
on the diameter of the blood vessels, blood density, blood
viscosity, and relevant parameters. In capillaries, the average
velocity is around 0.3 mm/s. At normal conditions, the blood
flow velocity (Elad and Einav 2003) in the aorta is between 3
and 5 m/s, while in large arteries it is about 7 and 10 m/s, and
in small arteries it is 15 and 35 m/s. The traveling speed of
the bionanorobots will rely on the blood flow velocity. Fla-
gellar motors allow bacteria to move at a speed up to
140 μm/s (Neethirajan et al. 2012) with directional reversals
occurring approximately 1/s. Based on the results of our
nano-porous microfluidic platform-assisted chemotaxis ex-
periments of measuring bacterial velocity, and the nanoscale
imaging of the flagellar motor using atomic force micro-
scope, we estimate that the speed (Neethirajan et al. 2012)
of bionanorobot will be in the range of 25 to 140 μm/s. The
speed will depend on the size of the robot and the number of
sensor components and its architecture.
Lymphoma and leukemia are the most common types of
blood cancer cells of the human biological system. Leukemia
is a cancer of the bone marrow or blood cells while lympho-
ma is a cancer that starts in the lymphatic system or in the
lymph nodes. These two types of cancer may appear similar
in size or shape most of the time and may even have similar
chemical signatures. The similarity between lymphoma and
leukemia tumors, possibilities in inaccurate measurements,
and overlap of the thermal, magnetic, and chemical proper-
ties surrounding the malignant and beneficial tumor cells and
the ever changing environment of the human body can cause
a lot of uncertainty inside the human body. An incorrect
diagnosis and treatment will not eradicate the cancer but
may cause additional harm, which is why it is important for
the bionanorobots to be able to handle uncertainty. The
reasons for using fuzzy logic system in assisting the
bionanorobot towards navigation and drug delivery is two-
fold: (1) The uncertainty in sensory reading that exists in real
life as well as the recommended drug dosages often
expressed in a range (as opposed a fixed number) can be
interpreted efficiently and (2) it would be possible to design
and fabricate the complex structure of bionanorobot by com-
bining multiple rules to handle the sophisticated environ-
ments. The motivation for developing the fuzzy control
system includes the need for precise control of drug delivery
for the two therapeutic agents (doxorubicin and cyclospor-
ine), if both are present in surplus.
2 Development of intelligent system
In clinical treatment, the use of bionanorobots will be done
with intravenous injection (Cavalcanti et al. 2008b; Elad and
Einav 2003). This method releases the robots directly into
the patients' bloodstream. Bio-actuation mechanisms of the
bionanorobots will facilitate swimming and swarming be-
havior inside the blood vessels. A bionanorobot needs to
travel through the bloodstream to reach its target, i.e.,
tumorous cell. Blood contains components such as throm-
bocytes, leukocytes, erythrocytes, and plasma, and hence,
the robot will experience a cluttered and unstructured en-
vironment during this traveling process. A major task for a
bionanorobot is to efficiently maneuver itself to the malig-
nant tumor cells. To do so, the robot must be equipped with
sensors to clearly detect the environment, find its path, and
avoid obstacles. More importantly, the robot should recog-
nize the healthy and malignant tumor cells and clearly
differentiate them. Due to the sensor noise, uncertainty,
and unknown parameters, accomplishing these tasks is
challenging mainly because of the robot's ability to effec-
tively handle the uncertain information during decision
making such as distinguishing between malignant tumors
and beneficial cells, differentiating lymphoma and leuke-
mia type tumor cells, and determining the amount of drug
dosage to be delivered.
A bionanorobot (Fig. 1) is made of (a) sensors and (b) an
on-board controller to fulfill its mission. It is possible to
prototype bionanorobots with multiple sensors (Lenaghan
et al. 2013) and nano-actuators (Ghaffari et al. 2012) using
molecular dynamics simulation and DNA or peptides
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(Hamdi and Ferreira 2008). With regards to the sensors, a
temperature sensor or a thermistor, flexi force sensor, pho-
todiode, strain gauge, and a magnetometer are used that
allow the robot to make a new trajectory planning decision,
identify the obstacles, and distinguish healthy and malignant
cells. The bionanorobot relies on the sensors to detect and
search the tumor cells using intelligent algorithms. Increased
temperature in a zone or regional hyperthermia is related to
non-neurological vasodilation and angiogenesis inside the
tumor (Zhang et al. 2008). In the human body, temperature
changes and generally increases in the inflamed tissues and
the area surrounding the tumor cells. The temperature can be
up to 2 °C higher for a malignant tumor (McDevitt et al.
2001). This property makes temperature an effective indica-
tor for diagnosing tumors at the nanoscale range. So, a
sudden or significant change in temperature occurring every
time is an indicator (Zhang et al. 2008) for the robot to
identify the malignant tumor cells. The robot's thermal sen-
sor will measure the temperature and make the decisions
accordingly. While the movement of the robot will be most-
ly in a linear fashion, it will also be able to scan all directions
by taking a circular fashion using the movement of the
cameras/photodiodes of the parts of the robot. In addition
to sensors, a bionanorobot will also have a nano-controller
on the board to collect the sensory data and make intelligent
decision accordingly. To be able to swim in the biological
body fluids in the narrow channels and to avoid trapping
inside the 4-μm retinal capillaries or the 1- to 2-μm
splenofenestral slits, the bionanorobot will be designed with
helical flagella (Fig. 1) propellers (Subramanian et al. 2009).
Upon successful delivery of the drugs, this flagella propeller
crawling mobility of the bionanorobot will facilitate the
transport through the excretory system for removal from
the blood through either the liver or kidney system.
Cells and tissues in the human body give off measurable
electromagnetic impulses. Both cancer and normal cells
possess the ability to utilize electromagnetic fields. The
structure, size, and the metabolic profiles of cancer cells do
not allow utilizing the electrical property in the same fashion
as normal cells. The electrical potential of the cell membrane
of cancer cells is lower with disrupted electrical connections
than the healthy cells (Gonzalez et al. 2012). Frohlich's
theory of coherent excitation (Frohlich 1983) and the change
in the generation of endogenous electromagnetic field
caused due to the vibrations in electrical polar structures
(Pokorny et al. 2008) surrounding the cells hypothesize that
magnetic property could be effectively used as a method for
discriminating between normal tissue and malignant tumors.
Bionanorobots can be designed to detect the difference in the
electromagnetic field between the cancer and healthy cells.
As per the law of magnetic force, the nearby healthy cell may
attract the nanorobot compared to a distant cancer cell which
might result in a false call. Hence, magnetic property alone
cannot be used by the bionanorobot for identifying cancer-
ous cells. When the magnetism and temperature-determined
thresholds are exceeded, the bionanorobot will attach to the
cell and take a pH (chemical signature) reading. The pH of
human blood (Waugh and Grant 2004) is slightly alkaline,
ranging from 7.35 to 7.45. As the tumor cell population
grows, the oxygen in the surrounding tissue is used up. As
anaerobic conditions develop, lactic acid begins to build up
as a by-product of the hydrolysis of ATP. This may effec-
tively lower the pH value, and therefore, the pH of the area
surrounding the cell can be used for identifying tumors.
Hence, an integrated approach of incorporating temperature
measurement along with magnetic and chemical (protein
expressions or pH) sensing will be an ideal method for the
bionanorobots for effective diagnosis of malignant tumors.
When a tumor cell has been identified and the bionanorobot
has attached to the cell, it must then correctly diagnose the
cancer before it can treat it effectively. Cancer antigen or
carbohydrate antigens 125 (CA125) and 19-9 (CA19-9) are
glycoprotein molecules that are expressed on the surface of
tumor cells. By identifying the concentrations of these markers,
the bionanorobot can determine the type of cancer present. An
elevated level of CA125 markers suggests the tumor is lym-
phoma and above normal levels of CA19-9 suggests it is
leukemia. Unfortunately, the diagnosis is not as simple as
identifying one type of glycoprotein since both can be
expressed in either type of cancer. This makes the fuzzy logic
Fig. 1 a Schematic illustration of the bionanorobots manoeuvering
inside the blood vessel. b Bionanorobot's drug delivery to the tumor
cell through attachment on the cell surface
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decision-making system a valuable tool for the bionanorobots
to determine the diagnosis of the tumor.
Nanocarriers (Hu and Zhang 2012) such as bionanorobots
that can carry two or more types of therapeutic payloads will
promote synergism through controlled combinatorial drug
delivery for overcoming drug resistances or possibly treating
multiple types of cancer. Cyclosporin is an immunosuppres-
sant that reduces the nuclear expressions of HTLV-1Tax
proteins of the leukemia cells making cyclosporin a useful
agent for tumor treatment when combined with other anti-
cancer agents (Ozaki et al. 2007). Doxorubicin is an
anthracycline antibiotic that treats tumor cells by interca-
lating DNA. The combination of doxorubicin and cyclo-
sporin drugs at different concentrations has been shown to
eradicate both lymphoma and leukemia (Xia and Smith
2012; Soma et al. 2000). After the drugs will be admin-
istered, the bionanorobot will detach and continue
searching for other tumor cells. Upon sensing the vacant
drug storage chamber with the strain gauge data, the
bionanorobot will be flushed out from the body through
the excretory system.
The environment surrounding the bionanorobots during
navigation and the sensors embedded on the robot's body
may be influenced by several uncertainty parameters.
Weights, age, sex, genetic factors, tolerance, physical condi-
tion of the patient, time of administration, and drug interac-
tion are few factors that influence the oncologist's recom-
mendation of the drug dosage to the cancer patient. Hence,
the drug dosages required for treating the cancer cells cannot
be represented by a fixed value. At the microscale range, due
to the nonselective uptake of the drugs into the cancer cells
and for enhancing the therapeutic indices, the dosage for
curing and treating cancer locally at the cellular level is best
represented as a range. To effectively maneuver the robot to
be able to diagnose and cure the tumorous cells, there is a
need to develop a decision-making system that can handle
uncertainties. Fuzzy logic is a powerful tool in handling
uncertainties associated with inherent sensor and environ-
mental noise in addition to the uncertainty in the drug dosage
levels. Furthermore, the noise rejection property of fuzzy
logic makes it a viable tool in our design. Figure 2 shows a
block diagram of the proposed intelligent system. The struc-
ture of a fuzzy logic system has three main steps. In the first
step, the sensory data, which contain uncertainties, are
fuzzified. The fuzzification process involves firing the mem-
bership functions. The second step is where the fuzzified
inputs are aggravated according to the designed rules. The
output of the inference mechanism is obtained by aggravat-
ing each individual rule output with a proper weighting.
Since the output of the inference mechanism is a fuzzy
number to get a real output, it needs to be defuzzified. The
final step is dedicated to defuzzification. The most common
defuzzification method is the centroid, which has been in this
intelligent system design. The output of the defuzzifier is a
real number that will be used by the bionanorobot for deci-
sion making and during navigation.
Relying on the input of sensory data from the
bionanorobots, the fuzzy logic system will be making
intelligent decisions for navigation and maneuvering and
for the diagnosis and drug delivery for the tumor cell. In
developing the fuzzy logic decision-making system, we
first design the rules. The rule structure is comprised of
the motion control rules for the navigation of biona-
norobots and the diagnosis and cure by drug delivery in
to the tumor cells. The motion control rules help the robot
to maneuver through the bloodstream while avoiding
obstacles/other robots. Avoiding collisions with other ro-
bots is a priority due to potential impact forces causing
destruction and the buffer impact damage from entrained
water molecules. The rules used to locate and attach to
tumors as well as the rules for detachment are included
in this section.
2.1 Bionanorobot rule structure list
2.1.1 Navigation rules
If obstacles (other than robots) are detected, then send a
signal to the control board to initiate the propeller for a
change in direction. Otherwise, continue navigation.
2.1.2 Collision avoidance (with other robots) rule
If the photodiode identifies another bionanorobot, then avoid
and apply a change of direction command. The following set
of rules determines the detection of the malignant cell.
2.1.3 Target identification rule
1. If the measured temperature from an obstacle is higher,
then move closer towards that particular object.
2. If the magnetic force of attraction is higher from an
obstacle or an object on the path of bionanorobot, then
move closer toward that object.
Fig. 2 Block diagram showing the design of the proposed intelligent
system for bionanorobot-assisted drug delivery in cancer treatment
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2.1.4 Detection and attachment rule
If the robot detects the optimum threshold temperature and
the magnetic force range indicating a tumorous cell, then
make contact and attach to that cell. The final sets of rules are
for curing by drug delivery.
2.1.5 Drug delivery rule
After the attachment on the surface of the tumor cell, if the
chemical concentration of peptide is minimal, then inject the
drug through the nanocannula inside the cell.
2.1.6 Mission complete rule
Upon successful delivery of drug into the cell, and based on the
weight of the drug delivery storage chamber of the bionanorobot
from the strain gauges, activate the flush-out mode. This mode
will allow the bionanorobot to travel to the urinary and excretory
system of the human body.
The following is specifically focused on the diagnosis and
cure for the tumor cells.
2.2 Diagnosis
Once the robot successfully identifies the tumor cells and is
attached to its surface, it must then diagnose the type of
cancer through intelligent decision-making process of the
system. This is achieved through using two tumor bio-
markers: CA125 and CA19-9. Both these markers are
expressed in lymphoma and leukemia cells, and hence, the
concentration and sensitivity of CA125 and CA19-9 can
serve as the determining variables for distinguishing the type
Fig. 3 Evaluation of
membership functions for fuzzy
logic controlled bionanorobot
assisted drug delivery system
Fig. 4 Diagnosis output for the
CA 125 marker versus sensitivity
and concentration
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of tumor cells. The cutoff values for the markers to detect
tumor cells are as follows:
Marker Concentration (U/ml) Sensitivity (%)
CA 125 1.7 to 32 80
CA 19-9 0 to 33 25.7
For this section, the designed intelligent system has two
inputs and two outputs. The inputs are concentration and
sensitivity of the two markers, and the two outputs will be
lymphoma and leukemia. The rule base system to determine
the likelihood of the tumor being either lymphoma or leuke-
mia is as follows:
1. First rule: If the concentration of CA 125marker is found
to be between 1.7 and 32 μg/ml or higher and a sensi-
tivity of 80 % or greater, then the tumor is considered to
be leukemic.
2. Second rule: If the concentration of CA 19-9 is between
0 and 33 μg/ml and with the sensitivity of 25.7 % or
higher, the tumor is diagnosed as lymphoma.
Since the concentration of the markers is not deterministic
(have an uncertainty range associated with them), it is suit-
able to use Mamdani fuzzy logic (Matthias et al. 2012)
structure for the diagnosis part, which enables incorporating
uncertainty in the rules. Unlike probabilistic-based Bayesian
approaches, which require prior knowledge about unknown
parameters, fuzzy logic does not require making assumptions
on the uncertainty and its structure. The nonlinear relation-
ship between input and output of the Mamdani approach has
unique advantage over backpropagation and neural networks
by offering reduced training and computing time (Agrawal
et al. 2012; Saritas et al. 2009). The implications of reduced
processing time involve a reduction in power consumption
and superior execution time of the bionanorobot. The flexi-
ble structure of the Mamdani-based fuzzy logic allows to
easily model complex uncertainties in the navigation and
drug delivery decision making of the bionanorobots. This
is usually achieved through proper design of the membership
functions to account for uncertainty: The membership func-
tions used to identify the concentration or sensitivity (of the
CA 125 or CA 19-9 markers) are Gaussian or Sigmoid and
are shown in Fig. 3. Figure 4 shows the diagnosis output
surface for the first rule for different concentration and
sensitivity of CA 125 marker.
2.3 Cure
The final section is to cure or treat the tumor cell through
drug delivery. Based on the diagnosis, the bionanorobot
needs to determine the dosage of the drugs to be delivered
to the cell. The outputs of the diagnosis decision making
system are then fed as inputs for the drug delivery and cure
decision-making system. The rules for the drug delivery
process are designed as follows:
1. First rule: If the diagnosis output identifies leukemia
with a chance of above a threshold (called S1), then a
dose of 3 ng/ml of cyclosporin and 62.8 ng/ml of doxo-
rubicin will be used to cure the tumor. S1 is considered
71 % in the design.
2. Second rule: If the diagnosis output identifies a chance
of the tumor being lymphoma greater than a threshold
(called S2), then the cure system will use 4,600 ng/ml of
Fig. 5 Membership functions
used in Section 5 to determine
the sensitivity levels of leukemia
and lymphoma
Table 1 Consequent rule parameters for drug dosage delivery to tumor




yD ¼ 3793:1xþ 806:9
Rule 2
yC ¼ 36:05xþ 13:95
yD ¼ 42:11xþ 291:89

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cyclosporin and 22.6 ng/ml of doxorubicin for cure. S2 is
considered 24 % in the design.
To assign the dosage in the interval of [S1 or S2, 100 %]
linearly, Takagi–Sugeno model is being deployed for this
particular functioning of the drug delivery by the
bionanorobot. The structure of the Takagi–Sugeno fuzzy
model enables linear mapping (Garibaldi et al. 2012), which
makes it a suitable choice for designing the effective drug
delivery dosage into the tumor cell. In the design of the
membership functions, we have assigned minimum and
maximum drug dosages to the intervals of the markers' cutoff
values, respectively, i.e., for the cutoff value of 71 % of the
CA 125 markers, the cyclosporin dosage of 3 ng/ml has been
assigned. This will ensure the maximum drugs will be
assigned when each marker's detected concentration is
100 %. The membership functions that were designed to
determine cyclosporin and doxorubicin sensitivities are
shown in Fig. 5. These values are used to identify the
required drug dosage.
The consequent parameters of the fuzzy system are sum-
marized in Table 1, where yC and yD represent the output
dosages for cyclosporin and doxorubicin, respectively.
When the three developed systems for navigation, diag-
nosis, and cure are combined, they comprise an intelligent
system that enables the bionanorobots to detect, identify, and
treat most cancers despite uncertainties and noise in the
biological system.
3 Simulations and results
To demonstrate the potential of the developed system, we
performed analyses on the cure section for different noise
levels up to 3 % using the Matlab. The differences between
the output dosages in cyclosporine and doxorubicin for
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different concentration levels that correspond to different
percentage noises are shown in Figs. 6 and 7. The dosage
differences for cyclosporine and doxorubicin of the CA 125
and the CA 19-9 are shown in Figs. 6 and 7, respectively.
Though there are small differences in the output dosages
determined by the developed intelligent systems, the results
prove the validity of the system's robustness to noise. The
dosages determined by the markers are considered indepen-
dent. However, the dosages can be easily combined through
weighting the average of the outputs, if a mixture of drugs is
needed. This demonstrates the flexibility of the fuzzy logic
system in incorporating complexity in the drug delivery
design.
The intelligence system for a bionanorobot requires the
ability to handle sensor noise and environment uncertainty.
Validation and testing the control rule that uses an increase in
temperature and magnetic properties to identify the tumor
cell by adding noise proved the robustness of the intelligent
system. The other control rules that used fuzzy logic were all
robust to noise levels up to 3 %. The diagnosis fuzzy system
was successful in handling noise appropriately beyond the
expected upper limit noise level of 3 %. The proposed
intelligent system was able to correctly diagnose the different
scenarios and was able to deliver the appropriate drug dos-
age. Future work will be focused on identifying the hybrid
combinations of dosages determined by different markers.
4 Conclusions
Nonlinear dynamics, profound variability, and uncertainty
inside the complex human body cause critical challenges for
controlled drug delivery. We propose a fuzzy logic-based
intelligent system to navigate bionanorobots inside the blood
vessels for diagnosis and curing by effective drug dosage
delivery into the tumor cells. The proposed intelligent system
has a flexible structure and its parameters can be tailor made
depending on the detecting sensors and the drug dosages as
required. The bionanorobot will aid in the development and
efficient delivery of unique combinations of drug cocktails
based on individual patients with different tumor expression
profiles. The fuzzy logic-assisted intelligent system of the
bionanorobot will reduce the false-positive rate in the diagno-
sis of tumor cells with increased sensitivity and thereby will
lead to improved drug delivery. The future work is focused on
enhancing the intelligent system structure and to validate its
performance in 3D simulation environments. Influenced by
nanotechnology, biomedical industry will see novel advances
with intelligent innovations such as bionanorobots in the near
future and will lead to effective drug delivery for cancer
treatment. The success of deployment of bionanorobots for
nanomedicine applications depends on the perception of con-
sumers and the regulations of government agencies.
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